Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 34

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Sep 14, 2009; 15(34): 4278-4283
Published online Sep 14, 2009. doi: 10.3748/wjg.15.4278

Table 3 Observed toxicity according NCI-CTC grading (n = 12)

Citation: Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283
URL: https://www.wjgnet.com/1007-9327/full/v15/i34/4278.htm
DOI: https://dx.doi.org/10.3748/wjg.15.4278

Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283 [PMID: 19750570 DOI: 10.3748/wjg.15.4278]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.